Literature DB >> 16189016

Human papillomavirus type 16 E1circumflexE4 contributes to multiple facets of the papillomavirus life cycle.

Tomomi Nakahara1, Woei Ling Peh, John Doorbar, Denis Lee, Paul F Lambert.   

Abstract

The life cycle of human papillomaviruses (HPVs) is tightly linked to the differentiation program of the host's stratified epithelia that it infects. E1(circumflex)E4 is a viral protein that has been ascribed multiple biochemical properties of potential biological relevance to the viral life cycle. To identify the role(s) of the viral E1(circumflex)E4 protein in the HPV life cycle, we characterized the properties of HPV type 16 (HPV16) genomes harboring mutations in the E4 gene in NIKS cells, a spontaneously immortalized keratinocyte cell line that when grown in organotypic raft cultures supports the HPV life cycle. We learned that E1(circumflex)E4 contributes to the replication of the viral plasmid genome as a nuclear plasmid in basal cells, in which we also found E1(circumflex)E4 protein to be expressed at low levels. In the suprabasal compartment of organotypic raft cultures harboring E1(circumflex)E4 mutant HPV16 genomes there were alterations in the frequency of suprabasal cells supporting DNA synthesis, the levels of viral DNA amplification, and the degree to which the virus perturbs differentiation. Interestingly, the comparison of the phenotypes of various mutations in E4 indicated that the E1(circumflex)E4 protein-encoding requirements for these various processes differed. These data support the hypothesis that E1(circumflex)E4 is a multifunctional protein and that the different properties of E1(circumflex)E4 contribute to different processes in both the early and late stages of the virus life cycle.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16189016      PMCID: PMC1235822          DOI: 10.1128/JVI.79.20.13150-13165.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  68 in total

1.  The minor capsid protein L2 contributes to two steps in the human papillomavirus type 31 life cycle.

Authors:  Sigrid C Holmgren; Nicole A Patterson; Michelle A Ozbun; Paul F Lambert
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

Review 2.  Papillomavirus DNA replication.

Authors:  P F Lambert
Journal:  J Virol       Date:  1991-07       Impact factor: 5.103

3.  Specific interaction between HPV-16 E1-E4 and cytokeratins results in collapse of the epithelial cell intermediate filament network.

Authors:  J Doorbar; S Ely; J Sterling; C McLean; L Crawford
Journal:  Nature       Date:  1991-08-29       Impact factor: 49.962

4.  Cooperation between different forms of the human papillomavirus type 1 E4 protein to block cell cycle progression and cellular DNA synthesis.

Authors:  Gillian L Knight; John R Grainger; Phillip H Gallimore; Sally Roberts
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

5.  Variant upstream regulatory region sequences differentially regulate human papillomavirus type 16 DNA replication throughout the viral life cycle.

Authors:  Walter G Hubert
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

6.  The full-length E6 protein of human papillomavirus type 16 has transforming and trans-activating activities and cooperates with E7 to immortalize keratinocytes in culture.

Authors:  S A Sedman; M S Barbosa; W C Vass; N L Hubbert; J A Haas; D R Lowy; J T Schiller
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

7.  Epitope-mapped monoclonal antibodies against the HPV16E1--E4 protein.

Authors:  J Doorbar; S Ely; N Coleman; M Hibma; D H Davies; L Crawford
Journal:  Virology       Date:  1992-03       Impact factor: 3.616

8.  The E5 gene from human papillomavirus type 16 is an oncogene which enhances growth factor-mediated signal transduction to the nucleus.

Authors:  P Leechanachai; L Banks; F Moreau; G Matlashewski
Journal:  Oncogene       Date:  1992-01       Impact factor: 9.867

9.  Expression and splicing patterns of human papillomavirus type-16 mRNAs in pre-cancerous lesions and carcinomas of the cervix, in human keratinocytes immortalized by HPV 16, and in cell lines established from cervical cancers.

Authors:  L Sherman; N Alloul; I Golan; M Durst; A Baram
Journal:  Int J Cancer       Date:  1992-02-01       Impact factor: 7.396

10.  Human papillomavirus type 16 E1 E4-induced G2 arrest is associated with cytoplasmic retention of active Cdk1/cyclin B1 complexes.

Authors:  Clare E Davy; Deborah J Jackson; Kenneth Raj; Woei Ling Peh; Shirley A Southern; Papia Das; Rina Sorathia; Peter Laskey; Kate Middleton; Tomomi Nakahara; Qian Wang; Phillip J Masterson; Paul F Lambert; Scott Cuthill; Jonathan B A Millar; John Doorbar
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

View more
  48 in total

1.  A cyclin-binding motif in human papillomavirus type 18 (HPV18) E1^E4 is necessary for association with CDK-cyclin complexes and G2/M cell cycle arrest of keratinocytes, but is not required for differentiation-dependent viral genome amplification or L1 capsid protein expression.

Authors:  Gillian L Knight; Alice G Pugh; Emma Yates; Ian Bell; Regina Wilson; Cary A Moody; Laimonis A Laimins; Sally Roberts
Journal:  Virology       Date:  2011-01-31       Impact factor: 3.616

2.  Targeting the human papillomavirus E6 and E7 oncogenes through expression of the bovine papillomavirus type 1 E2 protein stimulates cellular motility.

Authors:  Monique A Morrison; Richard J Morreale; Shailaja Akunuru; Matthew Kofron; Yi Zheng; Susanne I Wells
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

3.  Role of calpain in the formation of human papillomavirus type 16 E1^E4 amyloid fibers and reorganization of the keratin network.

Authors:  Jameela Khan; Clare E Davy; Pauline B McIntosh; Deborah J Jackson; Steven Hinz; Qian Wang; John Doorbar
Journal:  J Virol       Date:  2011-07-13       Impact factor: 5.103

4.  The fanconi anemia pathway limits human papillomavirus replication.

Authors:  Elizabeth E Hoskins; Richard J Morreale; Stephen P Werner; Jennifer M Higginbotham; Laimonis A Laimins; Paul F Lambert; Darron R Brown; Maura L Gillison; Gerard J Nuovo; David P Witte; Mi-Ok Kim; Stella M Davies; Parinda A Mehta; Melinda Butsch Kovacic; Kathryn A Wikenheiser-Brokamp; Susanne I Wells
Journal:  J Virol       Date:  2012-05-23       Impact factor: 5.103

5.  Human papillomaviruses: a growing field.

Authors:  Denise A Galloway
Journal:  Genes Dev       Date:  2009-01-15       Impact factor: 11.361

6.  Structural analysis reveals an amyloid form of the human papillomavirus type 16 E1--E4 protein and provides a molecular basis for its accumulation.

Authors:  Pauline B McIntosh; Stephen R Martin; Deborah J Jackson; Jameela Khan; Erin R Isaacson; Lesley Calder; Kenneth Raj; Heather M Griffin; Qian Wang; Peter Laskey; John F Eccleston; John Doorbar
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

7.  Human papillomavirus 18 E1^E4 protein interacts with cyclin A/CDK 2 through an RXL motif.

Authors:  Qingming Ding; Lili Li; Peter Whyte
Journal:  Mol Cell Biochem       Date:  2012-10-13       Impact factor: 3.396

8.  Phosphorylation of the human papillomavirus type 16 E1--E4 protein at T57 by ERK triggers a structural change that enhances keratin binding and protein stability.

Authors:  Qian Wang; Alan Kennedy; Papia Das; Pauline B McIntosh; Steven A Howell; Erin R Isaacson; Steven A Hinz; Clare Davy; John Doorbar
Journal:  J Virol       Date:  2009-02-11       Impact factor: 5.103

9.  Human cytomegalovirus protein pUL117 targets the mini-chromosome maintenance complex and suppresses cellular DNA synthesis.

Authors:  Zhikang Qian; Van Leung-Pineda; Baoqin Xuan; Helen Piwnica-Worms; Dong Yu
Journal:  PLoS Pathog       Date:  2010-03-19       Impact factor: 6.823

10.  Fanconi anemia deficiency stimulates HPV-associated hyperplastic growth in organotypic epithelial raft culture.

Authors:  E E Hoskins; T A Morris; J M Higginbotham; N Spardy; E Cha; P Kelly; D A Williams; K A Wikenheiser-Brokamp; S Duensing; S I Wells
Journal:  Oncogene       Date:  2008-11-17       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.